Avestar Capital’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.8M | Buy |
5,585
+386
| +7% | +$185K | 0.16% | 111 |
|
|
2026
Q1 | $2.56M | Sell |
5,199
-27
| -0.5% | -$14.7K | 0.16% | 104 |
|
|
2025
Q4 | $3.03M | Sell |
5,226
-597
| -10% | -$338K | 0.2% | 86 |
|
|
2025
Q3 | $2.82M | Buy |
5,823
+1,277
| +28% | +$594K | 0.18% | 99 |
|
|
2025
Q2 | $1.84M | Buy |
4,546
+362
| +9% | +$151K | 0.13% | 124 |
|
|
2025
Q1 | $2.08M | Buy |
4,184
+396
| +10% | +$214K | 0.18% | 101 |
|
|
2024
Q4 | $1.97M | Buy |
3,788
+590
| +18% | +$324K | 0.17% | 100 |
|
|
2024
Q3 | $1.98M | Buy |
3,198
+214
| +7% | +$127K | 0.2% | 92 |
|
|
2024
Q2 | $1.65M | Buy |
2,984
+1,052
| +54% | +$603K | 0.17% | 105 |
|
|
2024
Q1 | $1.12M | Buy |
1,932
+539
| +39% | +$302K | 0.12% | 143 |
|
|
2023
Q4 | $740K | Buy |
1,393
+258
| +23% | +$125K | 0.08% | 152 |
|
|
2023
Q3 | $575K | Buy |
1,135
+153
| +16% | +$81.5K | 0.08% | 152 |
|
|
2023
Q2 | $512K | Buy |
982
+30
| +3% | +$16.2K | 0.08% | 147 |
|
|
2023
Q1 | $549K | Buy |
952
+62
| +7% | +$34.9K | 0.1% | 135 |
|
|
2022
Q4 | $490K | Sell |
890
-56
| -6% | -$29.7K | 0.09% | 141 |
|
|
2022
Q3 | $480K | Buy |
946
+114
| +14% | +$63.8K | 0.12% | 124 |
|
|
2022
Q2 | $452K | Buy |
832
+9
| +1% | +$4.95K | 0.11% | 132 |
|
|
2022
Q1 | $486K | Buy |
823
+170
| +26% | +$97.7K | 0.08% | 232 |
|
|
2021
Q4 | $436K | Sell |
653
-34
| -5% | -$21.2K | 0.05% | 284 |
|
|
2021
Q3 | $393K | Sell |
687
-13
| -2% | -$7.13K | 0.05% | 303 |
|
|
2021
Q2 | $353K | Buy |
700
+20
| +3% | +$9.44K | 0.05% | 297 |
|
|
2021
Q1 | $330K | Buy |
680
+21
| +3% | +$10K | 0.07% | 232 |
|
|
2020
Q4 | $307K | Buy |
659
+38
| +6% | +$17.8K | 0.09% | 207 |
|
|
2020
Q3 | $300K | Sell |
621
-99
| -14% | -$40.9K | 0.1% | 162 |
|
|
2020
Q2 | $261K | Sell |
720
-46
| -6% | -$15.4K | 0.12% | 148 |
|
|
2020
Q1 | $217K | Buy |
766
+24
| +3% | +$7.57K | 0.12% | 145 |
|
|
2019
Q4 | $241K | Sell |
742
-2
| -0.3% | -$606 | 0.14% | 138 |
|
|
2019
Q3 | $217K | Buy |
744
+231
| +45% | +$66.1K | 0.13% | 145 |
|
|
2019
Q2 | $130K | Sell |
513
-56
| -10% | -$15.4K | 0.08% | 155 |
|
|
2019
Q1 | $134K | Sell |
569
-71
| -11% | -$17.7K | 0.09% | 156 |
|
|
2018
Q4 | $125K | Sell |
640
-79
| -11% | -$18.5K | 0.09% | 146 |
|
|
2018
Q3 | $152K | Buy |
719
+48
| +7% | +$11K | 0.09% | 147 |
|
|
2018
Q2 | $115K | Buy |
671
+36
| +6% | +$7.64K | 0.07% | 184 |
|
|
2018
Q1 | $110K | Buy |
635
+63
| +11% | +$13.2K | 0.07% | 162 |
|
|
2017
Q4 | $93K | Buy |
+572
| New | +$110K | 0.07% | 164 |
|
Other funds holding TMO
RG
ECSS
LT
Avestar Capital's TMO Position: Q2 2026 in Review
Avestar Capital increased its Thermo Fisher Scientific (TMO) stake by 7.4% in Q2 2026, buying an estimated $185K and bringing the position to 5,585 shares worth $2.8M. The position accounts for 0.16% of the portfolio, ranked #111.
Avestar Capital first reported a position in TMO in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.03M in Q4 2025. 1,153 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Avestar Capital held 5,585 shares of Thermo Fisher Scientific worth $2.8M as of Q2 2026.
- Avestar Capital bought 386 Thermo Fisher Scientific shares in Q2 2026, an estimated $185K.
- Thermo Fisher Scientific made up 0.16% of Avestar Capital's portfolio in Q2 2026, its #111 holding.
- Avestar Capital first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 35 quarters since.
- Avestar Capital's Thermo Fisher Scientific position peaked at $3.03M in Q4 2025.
- 1,153 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.